Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?Zacks Investment Research • 10/07/24
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of MedicineBusiness Wire • 09/16/24
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024Business Wire • 09/15/24
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in SeptemberBusiness Wire • 08/28/24
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue TrendsZacks Investment Research • 08/12/24
Argonne's Autonomie Express tool simulates real-world vehicle traffic to predict large-scale energy impactBusiness Wire • 08/07/24
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel RevenuesZacks Investment Research • 08/07/24
Invenra Highlights Exelixis' Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid TumorsBusiness Wire • 08/07/24
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/06/24
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateBusiness Wire • 08/06/24
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine TumorsBusiness Wire • 08/06/24
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024Business Wire • 07/23/24